114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
BBIBP-CorV 新冠疫苗对新生儿不良临床结局的安全性：一项前瞻性队列研究
Authors Muhetaier R, Zhang L, Ding G, Wang K , Li X
Received 9 May 2025
Accepted for publication 28 November 2025
Published 31 December 2025 Volume 2025:17 Pages 5747—5759
DOI https://doi.org/10.2147/IJWH.S539400
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Vinay Kumar
Reyilaimu Muhetaier,1 Luhan Zhang,2 Guifeng Ding,2 Kai Wang,3 Xiaoqin Li2
1School of Public Health, Xinjiang Medical University, Urumqi, 830017, People’s Republic of China; 2Xinjiang Clinical Medical Research Center for Perinatal Diseases, Maternal and Child Health Hospital of Urumqi, Urumqi, 830000, People’s Republic of China; 3School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830017, People’s Republic of China
Correspondence: Kai Wang, School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830017, People’s Republic of China, Email wangkaimath@sina.com
Abstarct:
Objective: The aim of this study is to evaluate the safety of preconception inoculation with an inactivated SARS-CoV-2 vaccine with respect to adverse birth outcomes in newborns, to elucidate the potential association between inactivated COVID-19 vaccination and birth outcomes, and to provide scientific evidence to inform future vaccine policy development.
Methods: In this study, a prospective cohort design is adopted, including913 mother–infant pairs among 2243 pregnant and postpartum women who delivered between January 2023 and May 31, 2023, at You’ai Hospital and the Maternal and Child Health Hospital in Urumqi. On the basis of the number of preconception doses of an inactivated SARS-CoV-2 vaccine, Poisson regression models were used to analyse the safety of preconception vaccination in terms of adverse birth outcomes in newborns.
Results: Among 913 participants, 13.8% were unvaccinated (n=126), while 1-, 2-, and 3-dose BBIBP-CorV recipients accounted for 2.4% (n=22), 17.9% (n=163), and 65.9% (n=602), respectively. Stratified analysis revealed no increased risk of adverse neonatal outcomes in any vaccinated group vs unvaccinated group (1-dose: RR 1.07 [0.67– 1.71]; 2-dose: 1.02 [0.80– 1.31]; 3-dose: 1.03 [0.84– 1.26]). Sensitivity analysis confirmed that there were no significant differences.
Conclusion: This study provides substantial evidence that prepregnancy BBIBP-CorV vaccination poses no safety concerns for neonatal outcomes. Clinically, these findings suggest that obstetricians should recommend COVID-19 vaccination during preconception counselling as a protective measure for future pregnancies. Public health implications include (1) supporting the integration of inactivated vaccines into prepregnancy health care programs to enhance immunity before gestation and (2) informing national policies to accelerate vaccine coverage among women of childbearing age, thereby reducing maternal–foetal risks in potential pandemics.
Keywords: SARS-CoV-2, inactivated COVID-19 vaccine, neonatal, vaccine safety, vaccine safety evaluation
1School of Public Health, Xinjiang Medical University, Urumqi, 830017, People’s Republic of China; 2Xinjiang Clinical Medical Research Center for Perinatal Diseases, Maternal and Child Health Hospital of Urumqi, Urumqi, 830000, People’s Republic of China; 3School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830017, People’s Republic of China
Correspondence: Kai Wang, School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi, 830017, People’s Republic of China, Email wangkaimath@sina.com
Abstarct:
Objective: The aim of this study is to evaluate the safety of preconception inoculation with an inactivated SARS-CoV-2 vaccine with respect to adverse birth outcomes in newborns, to elucidate the potential association between inactivated COVID-19 vaccination and birth outcomes, and to provide scientific evidence to inform future vaccine policy development.
Methods: In this study, a prospective cohort design is adopted, including913 mother–infant pairs among 2243 pregnant and postpartum women who delivered between January 2023 and May 31, 2023, at You’ai Hospital and the Maternal and Child Health Hospital in Urumqi. On the basis of the number of preconception doses of an inactivated SARS-CoV-2 vaccine, Poisson regression models were used to analyse the safety of preconception vaccination in terms of adverse birth outcomes in newborns.
Results: Among 913 participants, 13.8% were unvaccinated (n=126), while 1-, 2-, and 3-dose BBIBP-CorV recipients accounted for 2.4% (n=22), 17.9% (n=163), and 65.9% (n=602), respectively. Stratified analysis revealed no increased risk of adverse neonatal outcomes in any vaccinated group vs unvaccinated group (1-dose: RR 1.07 [0.67– 1.71]; 2-dose: 1.02 [0.80– 1.31]; 3-dose: 1.03 [0.84– 1.26]). Sensitivity analysis confirmed that there were no significant differences.
Conclusion: This study provides substantial evidence that prepregnancy BBIBP-CorV vaccination poses no safety concerns for neonatal outcomes. Clinically, these findings suggest that obstetricians should recommend COVID-19 vaccination during preconception counselling as a protective measure for future pregnancies. Public health implications include (1) supporting the integration of inactivated vaccines into prepregnancy health care programs to enhance immunity before gestation and (2) informing national policies to accelerate vaccine coverage among women of childbearing age, thereby reducing maternal–foetal risks in potential pandemics.
Keywords: SARS-CoV-2, inactivated COVID-19 vaccine, neonatal, vaccine safety, vaccine safety evaluation